Skip to content
10-Q

Quarterly Report

ZYVERSA THERAPEUTICS, INC. ZVSA

0001641172-25-009724

← back to feed
Filed
May 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 7, 2025 4.77M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $12M
Current Liabilities Q1 2025 · Dec 31, 2024 $11.23M
Total Liabilities Q1 2025 · Mar 31, 2025 $12.86M
Total Liabilities Q1 2025 · Dec 31, 2024 $12.08M
Current Assets Q1 2025 · Mar 31, 2025 $2.11M
Current Assets Q1 2025 · Dec 31, 2024 $1.72M
Total Assets Q1 2025 · Mar 31, 2025 $20.99M
Total Assets Q1 2025 · Dec 31, 2024 $20.6M
Shares Diluted Q1 2025 · Mar 31, 2024 623.6K sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$3.78M
Stockholders Equity Q1 2025 · Mar 31, 2024 $11.22M
Stockholders Equity Q1 2025 · Dec 31, 2023 $11.07M
Eps Diluted Q1 2025 · Mar 31, 2024 −$4.53
Eps Basic Q1 2025 · Mar 31, 2024 −$4.53
Sga Expense Q1 2025 · Mar 31, 2024 $2.31M
Rd Expense Q1 2025 · Mar 31, 2024 $512.94K
Net Income Q1 2025 · Mar 31, 2024 −$2.83M
Operating Income Q1 2025 · Mar 31, 2024 −$2.83M